


Satralizumab is an investigational medicine ^{1–4}

It is an experimental drug investigated as a potential future treatment for MOGAD in the METEOROID study





Satralizumab is a medicine given as a subcutaneous injection (administered under the skin).



IL-6 is thought to cause damage and disability associated with MOGAD.



Satralizumab is an investigational medicine (experimental drug), which means it has not yet been approved for the treatment of MOGAD.



There are no approved treatments for prevention of MOGAD relapses.

This study will help determine if using satralizumab to block IL-6 will prevent the damage and disability associated with attacks.



Two clinical trials showed that satralizumab is safe and works as a treatment for neuromyelitis optica spectrum disorder (NMOSD). Satralizumab has already been approved in over 80 countries for the treatment of NMOSD.